Brett Sandercock Sells 2,500 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,500 shares of ResMed stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $175.49, for a total transaction of $438,725.00. Following the sale, the chief financial officer now owns 86,775 shares in the company, valued at $15,228,144.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Brett Sandercock also recently made the following trade(s):

  • On Monday, August 17th, Brett Sandercock sold 2,500 shares of ResMed stock. The stock was sold at an average price of $177.55, for a total transaction of $443,875.00.
  • On Wednesday, July 15th, Brett Sandercock sold 2,500 shares of ResMed stock. The stock was sold at an average price of $196.98, for a total transaction of $492,450.00.

Shares of NYSE:RMD traded down $1.49 during mid-day trading on Wednesday, hitting $174.06. The company had a trading volume of 544,208 shares, compared to its average volume of 699,658. The firm has a fifty day moving average price of $183.19 and a 200 day moving average price of $170.00. The company has a market capitalization of $25.22 billion, a PE ratio of 40.76, a price-to-earnings-growth ratio of 2.62 and a beta of 0.36. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.53 and a quick ratio of 1.84. ResMed Inc. has a one year low of $108.85 and a one year high of $208.99.

ResMed (NYSE:RMD) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.36. The company had revenue of $770.30 million during the quarter, compared to analyst estimates of $755.01 million. ResMed had a net margin of 21.02% and a return on equity of 30.34%. ResMed’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 EPS. Research analysts expect that ResMed Inc. will post 4.73 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 24th. Shareholders of record on Thursday, August 20th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Wednesday, August 19th. This represents a $1.56 dividend on an annualized basis and a yield of 0.90%. ResMed’s dividend payout ratio (DPR) is presently 32.77%.

RMD has been the topic of several recent research reports. Goldman Sachs Group downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Oppenheimer boosted their price target on shares of ResMed from $200.00 to $210.00 in a research report on Thursday, August 6th. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “hold” rating and set a $184.00 price target on the stock. in a research report on Tuesday, August 11th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Thursday, August 6th. Finally, Bank of America downgraded shares of ResMed from a “buy” rating to an “underperform” rating in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company’s stock. ResMed currently has an average rating of “Hold” and an average target price of $186.00.

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in ResMed by 3.8% during the 1st quarter. Wellington Management Group LLP now owns 1,790 shares of the medical equipment provider’s stock valued at $264,000 after purchasing an additional 66 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in ResMed by 57.8% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 2,766 shares of the medical equipment provider’s stock valued at $407,000 after purchasing an additional 1,013 shares in the last quarter. Wells Fargo & Company MN increased its stake in ResMed by 6.2% during the 1st quarter. Wells Fargo & Company MN now owns 387,665 shares of the medical equipment provider’s stock valued at $57,098,000 after purchasing an additional 22,510 shares in the last quarter. Paloma Partners Management Co bought a new stake in ResMed during the 1st quarter valued at $489,000. Finally, Advisor Group Holdings Inc. bought a new stake in ResMed during the 1st quarter valued at $5,523,000. Institutional investors and hedge funds own 69.38% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

See Also: How to Track your Portfolio in Google Finance

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.